何峰, 张小霞. 奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响[J]. 蚌埠医科大学学报, 2013, 37(9): 1096-1098,1102.
    引用本文: 何峰, 张小霞. 奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响[J]. 蚌埠医科大学学报, 2013, 37(9): 1096-1098,1102.
    HE Feng, ZHANG Xiao-xia. The curative effect and immune function influence of oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer[J]. Journal of Bengbu Medical University, 2013, 37(9): 1096-1098,1102.
    Citation: HE Feng, ZHANG Xiao-xia. The curative effect and immune function influence of oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer[J]. Journal of Bengbu Medical University, 2013, 37(9): 1096-1098,1102.

    奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响

    The curative effect and immune function influence of oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer

    • 摘要: 目的:探讨奥沙利铂联合卡培他滨治疗胃癌的临床疗效、安全性及对患者免疫功能的影响。方法:按随机数字表法将52例胃癌患者分为观察组和对照组,各26例。对照组应用奥沙利铂联合氟尿嘧啶与亚叶酸钙,观察组应用奥沙利铂联合卡培他滨,比较2组患者的临床疗效、T细胞亚群含量变化及不良反应发生率。结果:对照组和观察组的临床总有效率分别为61.54%和65.38%,差异无统计学意义(P0.05);化疗2 d及化疗后,2组患者的CD3+、CD4+含量均较化疗前降低(P0.05~P0.01),且2组患者化疗后CD3+、化疗2 d和化疗后CD4+含量差异均有统计学意义(P0.05~P0.01);而2组CD8+含量在化疗前后均无明显变化(P0.05),2组间差异无统计学意义(P0.05);观察组恶心呕吐、手足综合征及粒细胞下降的发生率均低于对照组(P0.05~P0.01)。结论:奥沙利铂联合卡培他滨治疗胃癌临床疗效肯定,安全性高,可保护患者的T细胞亚群,对机体免疫力影响较小,利于患者康复,值得临床推广。

       

      Abstract: ObjectiveTo investigate the clinical curative effects, safety and immune function influence of oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer. Methods: Fifty-two patients with gastric cancer were randomly divided into treatment group and control group( 26 cases each group) .The control group were treated with oxaliplatin combined with 5-fluorouracil and calcium folinate.the treatment group were treated with oxaliplatin combined with capecitabine.The curative effects, levels of T cell subgroup and incidence of adverse reactions of two groups were compared.Results: The total effective rates of the control group and treatment group were 61.54% and 65.38%, the difference of which had no statistical significance( P 0.05) .Compared with before chemotherapy, the levels of CD3 + and CD4 + of two groups decreased after chemotherapy and 2 days in chemotherapy( P 0.05 to P 0.01) .The differences of the levels of CD3 + after chemotherapy and CD4 + after chemotherapy and 2 days in chemotherapy in two groups had statistical significance( P 0.05 to P 0.01) .The levels of CD8 + in two groups did not obviously change before and after chemotherapy, the difference of which had no statistical significance ( P 0.05) .The incidence of nausea and vomiting,hand-foot syndrome and granulocyte declining in treatment group were lower than those in control group( P 0.05 to P 0.01) . Conclusions:Oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer is good effects,high safety and little influence on immunity,which can protect the T cell subgroup, conducive to the rehabilitation of patients,be worthy of being widely applied in clinic.

       

    /

    返回文章
    返回